21st January 2020
Diaprost entered into an exclusive Research and Option Agreement with a Top 10 Pharmaceutical company strategic partner in October 2017. Diaprost now announces that its strategic partner has exercised its option to acquire rights to its h11B6 antibody.
Press release Diaprost jan 21 2020
4th October 2017
Diaprost have agreed terms for an exclusive Research and Option Agreement, inclusive of an upfront payment, research funding and potential development milestone payments for its h11B6 antibody for prostate cancer.
Pressmeddelande Diaprost 4 okt 2017
Press release Diaprost oct 4 2017
13th December 2016
A new publication in Science Translational Medicine demonstrates that in vivo targeting of the enzyme human kallikrein-related peptidase 2 (hK2) is a powerful tool that can be used for detection of prostate cancer and monitoring treatment by quantifying the activity of the androgen receptor pathway.
Pressmeddelande Diaprost 13 dec 2016
Press release Diaprost dec 13 2016